Evaluation of the cost of cervical cancer at the National Institute of Oncology, Rabat

  • Amine Cheikh
  • Sanaa El Majjaoui
  • Nabil Ismaili
  • Zakia Cheikh
  • Jamal Bouajaj
  • Chakib Nejjari
  • Amine El Hassani
  • Yahya Cherrah
  • Noureddine Benjaafar

Abstract

Introduction: The Cervical Cancer (CC) is one of the heavy and costly diseases for the population and the health system. We want to know through this study, the first in Morocco, the annual cost of the treatment of this disease at the National Institute of Oncology (NIO) in Rabat, we also want to explore the possibility of flat-rate management of this disease in order to standardize medical practices and improve reimbursement by health insurance funds. Methods: 550 patients were treated for their cervical cancer in the Rabat's NIO. Data of all of medical and surgical services offered to patients were collected from the NIO registry. The cost of care was assessed using the method of micro-costing. We will focus to the total direct cost of all the services lavished to patients in NIO. Results: The global cost was about US$ 1,429,673 with an average estimated at US$ 2,599 ± US$ 839. Radiotherapy accounts for 55% of total costs, followed by brachytherapy (27%) and surgery (7%). This three services plus chemotherapy influence the overall cost of care (p <0.001). Other services (radiology, laboratory tests and consultations) represent only 10%. The overall cost is influenced by the stage of the disease, this cost decreased significantly evolving in the stage of CC (p <0.001). Conclusion: The standardization of medical practices is essential to the equity and efficiency in access to care. The flat-rate or lump sum by stage of disease is possible and interesting for standardizing medical practices and improving the services of the health insurance plan.

Pan African Medical Journal 2016; 23

Author Biographies

Amine Cheikh
Team of Pharmacoepidemiology and Pharmacoeconomics, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco; Department of pharmacy, International Hospital Cheikh Zaid, Rabat, Morocco; Faculty of Medicine, Abulcasis University, Rabat, Morocco
Sanaa El Majjaoui
Department of Radiotherapy, National Institute of Oncology, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Nabil Ismaili
Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Zakia Cheikh
Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Jamal Bouajaj
Department of Radiotherapy, International Hospital Cheikh Zaid, Rabat, Morocco
Chakib Nejjari
Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco; Department of Epidemiology, Faculty of Medicine and Pharmacy, Hassan II University, Fes, Morocco
Amine El Hassani
Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco; Head of Hospital, International Hospital Cheikh Zaid, Rabat, Morocco
Yahya Cherrah
Team of Pharmacoepidemiology and Pharmacoeconomics, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Noureddine Benjaafar
Department of Radiotherapy, National Institute of Oncology, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Published
2016-07-15
Section
Articles

Journal Identifiers


eISSN: 1937-8688